PDS Biotechnology Corp — Director's Dealing 2016

Jun 24, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-06-21

Reporting Person: Ratcliffe Liam (Director)
Reporting Person: New Leaf Venture Partners, L.L.C. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-21	Stock Option (right to purchase)	$9.34	A	30000	Acquired	2026-06-21	Common Stock (30000)	Direct

Footnotes

F1: One third of the option shares vest upon each of the first, second, and third anniversaries of the Transaction Date.

F2: The option to purchase Common Stock is held directly by Liam Ratcliffe ("Ratcliffe"). Ratcliffe has contractually agreed with New Leaf Venture Partners, L.L.C. (the "Management Company") to exercise the option and sell the shares to be received upon exercise of the option only at the direction of the Management Company. Philippe Chambon, Jeani Delagardelle, Ronald M. Hunt, Vijay Lathi, Liam Ratcliffe and Craig Slutzkin, the officers of the Management Company, disclaim beneficial ownership of such option and shares to be received upon exercise of such option except to the extent of their pecuniary interest therein.